Der Pharmacia Lettre
Abstract
Author(s): S.Thirumurugu, V.Parthasarathy, D.C.Arumainayagam, R.Manavalan
The intestinal absorption of oral-anti diabetic drugs in type-II Diabetes mellitus is altered when
concomitantly administered with other drugs like, antacids, antinuclear drugs, antibiotics and
others. Drug therapy becomes more complex as many individuals are on multiple drug therapy
and administer many drugs during same period of time. An increasing number of drug related
problems caused by drug interactions extended to include drug- drug interactions, drug Ã?¢Ã?â?¬Ã?â?? food
interactions, drug-diseases interactions. A closer monitoring and supervision of drug therapy is
required so that drug related problems can be prevented or detected at an early stage. To find
out the pharmacokinetic changes of oral anti- diabetic drugs when administered with other
drugs meant for co-existing diseases. The following parameters should be standardized. They are
HPLC analytical methods, Study design, Software to calculate pharmacokinetic parameters. In
this article several HPLC methods of the analysis for anti-diabetic drugs, reports of in-vitro and
in-vivo studies of anti-diabetic drugs were discussed. According to the results the changes in
pharmacokinetic parameters of anti-diabetic drugs were observed and discussed. It is concluded
that bioavailability studies of anti-diabetic drugs to be conducted in human volunteers with
updated protocols and HPLC methods of analysis. To rectify the problems associated with
concomitant administration and for better management of Type Ã?¢Ã?â?¬Ã?â??II diabetes therapy.
